{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T16:10:34Z","timestamp":1764259834852},"reference-count":30,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["lrjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.leukres.2013.07.001","type":"journal-article","created":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T14:47:23Z","timestamp":1375368443000},"page":"1309-1314","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["FoxO3a and nilotinib-induced erythroid differentiation of CML-BC cells"],"prefix":"10.1016","volume":"37","author":[{"given":"Wei","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan-Nan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei-Fei","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo-Qiang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.leukres.2013.07.001_bib0005","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrc1567","article-title":"Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia","volume":"5","author":"Ren","year":"2005","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10.1016\/j.leukres.2013.07.001_bib0010","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.leukres.2013.07.001_bib0015","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N Engl J Med"},{"issue":"5405","key":"10.1016\/j.leukres.2013.07.001_bib0020","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2013.07.001_bib0025","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2174\/157339409789712726","article-title":"Life and death of leukemic cells under Bcr-Abl signaling control","volume":"5","author":"Kuroda","year":"2009","journal-title":"Curr Cancer Ther Rev"},{"issue":"11","key":"10.1016\/j.leukres.2013.07.001_bib0030","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.leukres.2013.07.001_bib0035","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2013.07.001_bib0040","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood.V99.9.3472","article-title":"High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR\/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance","volume":"99","author":"Branford","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2013.07.001_bib0045","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/sj.thj.6200319","article-title":"High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib","volume":"5","author":"Al-Ali","year":"2004","journal-title":"Hematol J"},{"issue":"11","key":"10.1016\/j.leukres.2013.07.001_bib0050","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1016\/j.clinthera.2008.11.014","article-title":"Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia","volume":"30","author":"Deremer","year":"2008","journal-title":"Clin Ther"},{"issue":"8","key":"10.1016\/j.leukres.2013.07.001_bib0055","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1182\/blood-2006-09-046888","article-title":"Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis","volume":"109","author":"Cortes","year":"2007","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.leukres.2013.07.001_bib0060","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.cell.2007.06.009","article-title":"AKT\/PKB signaling: navigating downstream","volume":"129","author":"Manning","year":"2007","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.leukres.2013.07.001_bib0065","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1097-2765(04)00213-8","article-title":"FoxO: linking new signaling pathways","volume":"14","author":"Arden","year":"2004","journal-title":"Mol Cell"},{"issue":"8","key":"10.1016\/j.leukres.2013.07.001_bib0070","doi-asserted-by":"crossref","first-page":"6411","DOI":"10.1074\/jbc.M211562200","article-title":"A member of Forkhead transcription factor FKHRL1 is a downstream effector of STI571-induced cell cycle arrest in BCR-ABL-expressing cells","volume":"278","author":"Komatsu","year":"2003","journal-title":"J Biol Chem"},{"issue":"12","key":"10.1016\/j.leukres.2013.07.001_bib0075","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1111\/j.1349-7006.2007.00623.x","article-title":"Active FKHRL1 overcomes imatinib resistance in chronic myelogenous leukemia-derived cell lines via the production of tumor necrosis factor-related apoptosis-inducing ligand","volume":"98","author":"Kikuchi","year":"2007","journal-title":"Cancer Sci"},{"issue":"3","key":"10.1016\/j.leukres.2013.07.001_bib0080","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.taap.2006.12.003","article-title":"The role of Forkhead-box class O (FoxO) transcription factors in cancer: a target for the management of cancer","volume":"224","author":"Reagan-Shaw","year":"2007","journal-title":"Toxicol Appl Pharmacol"},{"issue":"9584","key":"10.1016\/j.leukres.2013.07.001_bib0085","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","article-title":"Chronic myeloid leukaemia","volume":"370","author":"Hehlmann","year":"2007","journal-title":"Lancet"},{"issue":"9134","key":"10.1016\/j.leukres.2013.07.001_bib0090","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(98)03030-X","article-title":"Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"352","author":"Gratwohl","year":"1998","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.leukres.2013.07.001_bib0095","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/leu.2010.257","article-title":"Inhibition of Grb2 expression demonstrates an important role in BCR-ABL-mediated MAPK activation and transformation of primary human hematopoietic cells","volume":"25","author":"Modi","year":"2011","journal-title":"Leukemia"},{"issue":"16","key":"10.1016\/j.leukres.2013.07.001_bib0100","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1182\/blood-2009-04-215376","article-title":"BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells","volume":"115","author":"Schemionek","year":"2010","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2013.07.001_bib0105","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1158\/0008-5472.CAN-07-6858","article-title":"BCR\/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations","volume":"68","author":"Stoklosa","year":"2008","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.leukres.2013.07.001_bib0110","doi-asserted-by":"crossref","first-page":"54","DOI":"10.4236\/scd.2011.13006","article-title":"Bcr-Abl-mediated Raf kinase inhibitor protein suppression promotes chronic myeloid leukemia progenitor cells proliferation","volume":"1","author":"Kazunori","year":"2011","journal-title":"Stem Cell Discovery"},{"issue":"5","key":"10.1016\/j.leukres.2013.07.001_bib0115","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1084\/jem.20020519","article-title":"Crosstalk between BCR\/ABL oncoprotein and CXCR4 signaling through a Src family kinase in human leukemia cells","volume":"196","author":"Ptasznik","year":"2002","journal-title":"J Exp Med"},{"issue":"Pt 8","key":"10.1016\/j.leukres.2013.07.001_bib0120","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1242\/jcs.03430","article-title":"Bcr-Abl induces abnormal cytoskeleton remodeling, beta1 integrin clustering and increased cell adhesion to fibronectin through the Abl interactor 1 pathway","volume":"120","author":"Li","year":"2007","journal-title":"J Cell Sci"},{"key":"10.1016\/j.leukres.2013.07.001_bib0125","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/sj.leu.2405086","article-title":"Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors","volume":"22","author":"Konig","year":"2008","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.leukres.2013.07.001_bib0130","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1182\/blood-2009-05-222976","article-title":"FOXO3A as a key molecule for all-trans retinoic acid-induced granulocytic differentiation and apoptosis in acute promyelocytic leukemia","volume":"115","author":"Sakoe","year":"2010","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2013.07.001_bib0135","first-page":"1156","article-title":"Retinoid acid supports granulocytic but not erythroid differentiation of myeloid progenitors in normal bone marrow cells","volume":"7","author":"Gratas","year":"1993","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.leukres.2013.07.001_bib0140","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1002\/j.1460-2075.1992.tb05500.x","article-title":"The SCL gene product: a positive regulator of erythroid differentiation","volume":"11","author":"Aplan","year":"1992","journal-title":"EMBO J"},{"issue":"8","key":"10.1016\/j.leukres.2013.07.001_bib0145","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.1074\/jbc.M109.030296","article-title":"Targets of the Tal1 transcription factor in erythrocytes: E2 ubiquitin conjugate regulation by Tal1","volume":"285","author":"Lausen","year":"2010","journal-title":"Biol Chem"},{"issue":"6922","key":"10.1016\/j.leukres.2013.07.001_bib0150","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nature01345","article-title":"Haematopoietic stem cells retain long-term repopulating activity and multipotency in the absence of stem-cell leukaemia SCL\/tal-1 gene","volume":"421","author":"Mikkola","year":"2003","journal-title":"Nature"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212613002282?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212613002282?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,20]],"date-time":"2019-07-20T05:52:10Z","timestamp":1563601930000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212613002282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0145212613002282"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2013.07.001","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FoxO3a and nilotinib-induced erythroid differentiation of CML-BC cells","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2013.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}